Sunstone Life Science Ventures

Sunstone Life Science Ventures is an independent European venture capital investment firm. Our purpose – and passion – is to seek out, enable and empower the most promising life science therapeutics innovations.

We help turn new science into new products, improving outcome for patients. And we help create value for innovators, investors and health care systems around the world.

Read more… 

Are Series A radically growing?

If you are in the biotech venture capital business, it’s been difficult to avoid conversations about the increasing sizes of Series A financing rounds. We’ve been hearing and reading about a revival of biotech financing, including “Biotech Financing: darkest before...

Hans T. Scambye joins Sunstone as Venture Partner

Sunstone is delighted to announce that experienced biotech executive and CEO of Galecto Hans T. Schambye will be joining our team as new Venture Partner as of 1st February 2025. With a background as an MD and PhD Hans brings to Sunstone over 25 years of experience...

Neumirna Therapeutics secures euro 20M in Series A financing

Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini...

Saving Lives with Venture Capital

In 2023 we posted our thoughts on how to calculate the potential lifesaving impact of biotech venture capital (https://bit.ly/3z4mL0o) – and we promised to expand on the topic. Unfortunately, or rather fortunately, we got busy making investments in DioGenX, Kynexis...

The VC summer dream – the Fund Returner

The VC summer dream – the Fund ReturnerSunstone has over the past years continuously highlighted observations and learnings from successes in European biotech. The learnings have consolidated, tuned and verified our current investment strategy. Sunstone is today...

Investment Strategy

Sunstone Life Science Ventures invests in early-stage life science companies developing novel therapeutics for humans.  

Read more…

Funds

Our portfolio is managed through a series of funds. Fund IV, focusing solely on therapeutics, is actively pursuing new investment opportunities.

Read more…

People

As a team, we represent a broad range of highly relevant education, experience and competencies. Come on in and meet the team.

Read more…

Portfolio

An overview of the companies in our portfolio – currently active, completed M&As and completed IPOs.

Read more…

News

Newest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.

Read more…

Contact

Find our visiting address, contact info and some guidance and a contact form for submitting projects for evaluation.

Read more…

New science becomes new products

Since the inception of Sunstone in 2007, we have contributed in bringing several new drugs into the market and have supported a large number of clinical trials:

New drugs approved

Pre-clinical drug candidates

Clinical phase 1 studies

Clinical phase 2 studies

Clinical phase 3 studies

Sunstone Life Science Ventures is supported by InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing